Global Bronchiectasis Drugs Market Outlook 2019-2023 | Availability of Low-Cost Off-Label Generics to Boost Market Growth | Technavio
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190823005143/en/
Technavio has published a new market research report on the global bronchiectasis drugs market from 2019-2023. (Graphic: Business Wire)
Read the 131-page research report with TOC on "Bronchiectasis drugs Market Analysis Report by product (antibiotics, expectorants, and other drugs) and geography (Asia, Europe, North America, and ROW) 2019 – 2023”. Request a Free Sample Report
The market is driven by the availability of low-cost off-label generics. Also, the increasing cases of associated risk factors is expected to further boost the growth of the bronchiectasis drugs market.
The global bronchiectasis drugs market has witnessed the launch of several off-label generics over the past few years. Generic drugs contain the same active pharmaceutical ingredient (API) as branded drugs and are launched in the market shortly after a branded drug loses its patent exclusivity. As the cost of these drugs is also much lower in comparison to novel drugs, the approval and launch of these low-cost generics is expected to boost market growth during the forecast period.
The increasing cases of associated risk factors is another key factor that will drive the growth of the bronchiectasis drugs market size. Bronchiectasis frequently occurs secondary to other health conditions such as inflammatory bowel disease, humoral immunodeficiency, rheumatologic diseases, COPD, cystic fibrosis, several lung infections such as pneumonia and tuberculosis. The prevalence of these diseases is high across the world, which will lead to an increase in the demand for bronchiectasis drugs during the forecast period.
For More Information: Speak to an Analyst
The report includes detailed profiles of the leading companies & prominent vendors of the market:
- Endo International Plc
- GlaxoSmithKline Plc
- Neopharma LLC
- Pfizer Inc.
- Reckitt Benckiser Group Plc
Market Segmentation by Product:
The bronchiectasis drugs market can be broadly categorized into the following segments:
- Other drugs
Key Regions for the Bronchiectasis Drugs Market:
Featuring a breakdown of region-wise market shares until 2019.
- North America
Some of the key topics covered in the report include:
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market size and forecast
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Competitive scenario
Related Reports on Pharmaceuticals are:
Anti-Obesity Drugs Market – Global Anti-Obesity Drugs Market by mechanism of action (centrally-acting anti-obesity drugs and peripherally acting anti-obesity drugs), class of obesity (Class I anti-obesity drugs, Class II anti-obesity drugs, and Class III anti-obesity drugs), and geography (the Americas, APAC, and EMEA).
Pericarditis Drugs Market – Global Pericarditis Drugs Market by product (NSAIDs, colchicine, and others) and geography (Asia, Europe, North America, and ROW).
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Source: Technavio Research